. 2017 Jul 1;24(7):643–659. doi: 10.5551/jat.39917

Table 2. Characteristics of SCH subjects: Pre-to-Post Treatment (INCLUDED ONLY STUDIES THAT DISCUSSED TREATMNET OF SCH).

Authors	N (SCH): Pre-Rx/Post-Rx; % Females	JADAD Score	Primary disease	Rx. given	Dose of Thyroxin (µg/day)	Duration of Rx. (Mo)	TSH (mIU/L) in SCH (pre-Rx)	TSH (mIU/L) in SCH (Post-Rx)	Change	% change	CIMT (mm) in SCH (Pre-Rx)	CIMT (mm) in SCH (Post-Rx)	Change	% change
Monzani et al. 2004¹⁸⁾	23/23; 82%	4	SCH	T4	25	6	6.03 ± 8.4	1.32 ± 1.7	−4.71	−78%	0.76 ± 0.14	0.67 ± 0.13	−0.09	−12%
Duman et al. 2007²³⁾	20/20; 100%	4	SCH	T4	25	8	10.9 ± 5.8	2.0 ± 1.1	−8.9	−82%	0.65 ± 0.99	0.55 ± 0.08	−0.1	−15%
Adrees et al. 2009²⁰⁾	56/52; 100%	1	SCH	T4	50	18	13.2 ± 4.5	1.6 ± 1.8	−11.6	−88%	0.82 ± 0.2	0.71 ± 0.2	−0.11	−13.4%
Kim et al. 2009¹⁷⁾	36/28; 86.1%	3	SCH	T4	67	18	11.48 ± 4.70	1.26 ± 3.30	−10.22	−89%	0.67 ± 0.11	0.60 ± 0.10	−0.07	−10%
Kebapcilar et al. 2010¹⁵⁾	38/38; 82%	3	SCH	T4	25–50	6	11.26 ± 7.54	2.29 ± 1.43	−8.97	−80%	0.64 ± 0.13	0.63 ± 0.12	−0.01	−1.6%
Cabral et al. 2011³⁰⁾	14/14; 100%	4	SCH	T4	44.23	12	6.79 ± 2.0	3.02 ± 0.89	−3.77	−56%	0.66 ± 0.11	0.66 ± 0.15	0	0%
Koroglu et al. 2012²⁴⁾	30/30; 97%	4	SCH	T4	50	6	7.5 ± 1.5	3.6 ± 0.6	−3.9	−52%	NR	NR	NA	NA
Akkoca et al. 2014²¹⁾	20/20; 75%	3	SCH	T4	NR	7	8.97 ± 1.1	2.94 ± 0.43	−6.03	−67%	0.74 ± 0.63	0.43 ± 0.32	−0.31	−42%
Unsal et al. 2014²⁵⁾	56/56; 91%	1	SCH	T4	25–50	6	6.77 ± 2.90	2.73 ± 1.17	−4.04	−60%	0.53 ± 0.11	0.51 ± 0.13	−0.02	2%
Yazıcı et al. 2014²⁸⁾	23/23; 98%	4	SCH	T4	NR	6	5.9 ± 1.2	1.7 ± 0.9	−4.2	−71%	0.51 ± 0.09	0.46 ± 0.07	−0.05	10%
Cerbone et al. 2016²⁶⁾	39/39; 51%	2	SCH	T4	50	24	6.30 ± 1.01	2.82 ± 1.31	−3.48	−55%	0.44 ± 0.08	0.46 ± 0.07	0.02	4.5%
Niknam et al. 2016²⁷⁾	25/25; 60%	1	SCH	T4	50	2	7.19 ± 1.29	2.56 ± 0.69	−4.63	−64%	0.56 ± 0.09	0.57 ± 0.08	0.01	2%

The JADAD score/scale or the Oxford quality scoring system, is a procedure to independently assess the methodological quality of a clinical trial. SCH = Subclinical Hypothyroidism, TSH = Thyroid stimulating hormone.